| Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery A Lombardo, P Genovese, CM Beausejour, S Colleoni, YL Lee, KA Kim, ... Nature biotechnology 25 (11), 1298-1306, 2007 | 1182 | 2007 |
| An unbiased genome-wide analysis of zinc-finger nuclease specificity R Gabriel, A Lombardo, A Arens, JC Miller, P Genovese, C Kaeppel, ... Nature biotechnology 29 (9), 816-823, 2011 | 744 | 2011 |
| Targeted genome editing in human repopulating haematopoietic stem cells P Genovese, G Schiroli, G Escobar, T Di Tomaso, C Firrito, A Calabria, ... Nature 510 (7504), 235-240, 2014 | 719 | 2014 |
| Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer E Provasi, P Genovese, A Lombardo, Z Magnani, PQ Liu, A Reik, V Chu, ... Nature medicine 18 (5), 807-815, 2012 | 573 | 2012 |
| Site-specific integration and tailoring of cassette design for sustainable gene transfer A Lombardo, D Cesana, P Genovese, B Di Stefano, E Provasi, ... Nature methods 8 (10), 861-869, 2011 | 405 | 2011 |
| CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma M Casucci, B Nicolis di Robilant, L Falcone, B Camisa, M Norelli, ... Blood, The Journal of the American Society of Hematology 122 (20), 3461-3472, 2013 | 401 | 2013 |
| Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response G Schiroli, A Conti, S Ferrari, L Della Volpe, A Jacob, L Albano, S Beretta, ... Cell stem cell 24 (4), 551-565. e8, 2019 | 290 | 2019 |
| Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 G Schiroli, S Ferrari, A Conway, A Jacob, V Capo, L Albano, T Plati, ... Science translational medicine 9 (411), eaan0820, 2017 | 230 | 2017 |
| Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases MC Bonini, P Genovese, PD Gregory, MC Holmes, L Naldini, D Paschon, ... US Patent 8,956,828, 2015 | 224 | 2015 |
| Hepatocyte‐targeted expression by integrase‐defective lentiviral vectors induces antigen‐specific tolerance in mice with low genotoxic risk J Mátrai, A Cantore, CC Bartholomae, A Annoni, W Wang, ... Hepatology 53 (5), 1696-1707, 2011 | 158 | 2011 |
| Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking S Ferrari, A Jacob, S Beretta, G Unali, L Albano, V Vavassori, D Cittaro, ... Nature biotechnology 38 (11), 1298-1308, 2020 | 151 | 2020 |
| Cyclosporine H overcomes innate immune restrictions to improve lentiviral transduction and gene editing in human hematopoietic stem cells C Petrillo, LG Thorne, G Unali, G Schiroli, AMS Giordano, F Piras, ... Cell Stem Cell 23 (6), 820-832. e9, 2018 | 113 | 2018 |
| Targeted gene therapy and cell reprogramming in F anconi anemia P Rio, R Baños, A Lombardo, O Quintana‐Bustamante, L Alvarez, ... EMBO molecular medicine 6 (6), 835-848, 2014 | 97 | 2014 |
| NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease S Mastaglio, P Genovese, Z Magnani, E Ruggiero, E Landoni, B Camisa, ... Blood, The Journal of the American Society of Hematology 130 (5), 606-618, 2017 | 75 | 2017 |
| Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients B Diez, P Genovese, FJ Roman‐Rodriguez, L Alvarez, G Schiroli, ... EMBO molecular medicine 9 (11), 1574-1588, 2017 | 68 | 2017 |
| Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome V Vavassori, E Mercuri, GE Marcovecchio, MC Castiello, G Schiroli, ... EMBO Molecular Medicine 13 (3), e13545, 2021 | 47 | 2021 |
| Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism … AR Elia, P Circosta, D Sangiolo, C Bonini, L Gammaitoni, S Mastaglio, ... Human gene therapy 26 (4), 220-231, 2015 | 18 | 2015 |
Luigi NaldiniDirector, SR-TIGET, San Raffaele Telethon Institute for Gene Therapy, Professor of Tissue BiologyAdresse e-mail validée de hsr.it
